Mitchell Thorn
Overview
Explore the profile of Mitchell Thorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen H, Alexander K, Collinge M, Hickey J, Lanz T, Li J, et al.
Mol Ther
. 2024 Dec;
PMID: 39673130
RNA medicines have become a promising platform for therapeutic use in recent years. Understanding the immunomodulatory effects of novel mRNA-lipid nanoparticles (LNPs) is crucial for future therapeutic development. An in ...
2.
Li W, Crouse K, Alley J, Frisbie R, Fish S, Andreyeva T, et al.
J Pharmacol Exp Ther
. 2023 May;
386(1):80-92.
PMID: 37142443
Blocking chemokine receptor C-C chemoattractant cytokine (chemokine) receptor (CCR) 6-dependent T cell migration has therapeutic promise in inflammatory diseases. PF-07054894 is a novel CCR6 antagonist that blocked only CCR6, CCR7,...
3.
Katz S, Burga R, McCormack E, Wang L, Mooring W, Point G, et al.
Clin Cancer Res
. 2015 Apr;
21(14):3149-59.
PMID: 25850950
Purpose: Chimeric antigen receptor-modified T cells (CAR-T) have demonstrated encouraging results in early-phase clinical trials. Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases, a major cause of death...
4.
Burga R, Thorn M, Point G, Guha P, Nguyen C, Licata L, et al.
Cancer Immunol Immunother
. 2015 Apr;
64(7):817-29.
PMID: 25850344
Chimeric antigen receptor-modified T cell (CAR-T) technology, a promising immunotherapeutic tool, has not been applied specifically to treat liver metastases (LM). While CAR-T delivery to LM can be optimized by...
5.
Thorn M, Hudson A, Kreeger J, Kawabe T, Bowman C, Collinge M
J Immunotoxicol
. 2014 Nov;
12(4):350-60.
PMID: 25412622
Delayed-type hypersensitivity (DTH) is a T-cell-mediated immune response that may be used for immunotoxicity testing in non-clinical species. However, in some cases DTH assays using T-dependent antigens may be confounded...
6.
Thorn M, Point G, Burga R, Nguyen C, Espat N, Katz S
J Leukoc Biol
. 2014 Aug;
96(5):883-94.
PMID: 25085111
LM escape immune surveillance, in part, as a result of the expansion of CD11b+MC, which alter the intrahepatic microenvironment to promote tumor tolerance. HBC make up a significant proportion of...
7.
Licata L, Nguyen C, Burga R, Falanga V, Espat N, Ayala A, et al.
J Leukoc Biol
. 2013 Jul;
94(4):813-23.
PMID: 23883516
Biliary obstruction is a common clinical problem that is associated with intrahepatic inflammation and impaired immunity. PD-1 is well known to mediate T cell dysfunction but has been reported to...
8.
Katz S, Burga R, Naheed S, Licata L, Thorn M, Osgood D, et al.
J Transl Med
. 2013 Feb;
11:46.
PMID: 23433424
Background: Imatinib mesylate is an effective treatment for metastatic gastrointestinal stromal tumor (GIST). However, most patients eventually develop resistance and there are few other treatment options. Immunotherapy using genetically modified...
9.
Collinge M, Thorn M, Peachee V, White Jr K
J Immunotoxicol
. 2013 Jan;
10(4):341-8.
PMID: 23282408
Establishing an in vivo cell-mediated immunity (CMI) assay, such as the delayed-type hypersensitivity (DTH) assay, has been identified as an important gap and recommended to receive highest priority for new...
10.
Thorn M, Piche-Nicholas N, Stedman D, Davenport S, Zhang N, Collinge M, et al.
Birth Defects Res B Dev Reprod Toxicol
. 2012 Sep;
95(5):363-75.
PMID: 22969064
Background: There is concern about embryo-fetal exposure to antibody-based biopharmaceuticals based on the increase of such therapies being prescribed to women of childbearing potential. Therefore, there is a desire to...